Coskun et al [32] have reported a reduction in serum VEGF levels in postmenopausal breast cancer patients receiving hormonal therapy in the presence of a normal endometrium, with increased circulating VEGF in patients with endometrial thickening. This evidence concerns the gene VEGFA and breast carcinoma.